Table 1 Clinicopathological characteristics for HR + N + patients in the Trans-aTTom cohort
Trans-aTTom HR + pN + (N = 789) | |
|---|---|
Age | |
< 50 | 101 (13%) |
50–59 | 272 (34%) |
60–69 | 218 (28%) |
≥ 70 | 198 (25%) |
Menopause status | |
Pre | 25 (3%) |
Post | 679 (86%) |
Peri | 28 (4%) |
Not known | 57 (7%) |
Tumor size | |
T1 | 362 (46%) |
T2 | 336 (43%) |
T3 | 30 (4%) |
Not known | 61 (8%) |
Histological grade | |
Well differentiated | 118 (15%) |
Moderately differentiated | 369 (47%) |
Poorly differentiated | 161 (20%) |
Not known | 141 (18%) |
ER status | |
Negative | 17 (2%) |
Positive | 771 (98%) |
Not known | 1 (0%) |
PR status | |
Negative | 69 (9%) |
Positive | 717 (91%) |
Not known | 3 (0%) |
HER2 status | |
Negative | 711 (90%) |
Positive | 72 (9%) |
Not known | 6 (1%) |